B52T38 , after what happened with Remdesivir study , changing primary endpoint at the end of the study, and then approving within 2-3 days , with uch a poor results ...
and many safe , much better drugs going thru delays ,
I don't know how to answer your question , maybe others will..
GLTU.
IMO.